Evidence map›Paper›PMID 35143561›Full record

ArticlePloS one2022

ADP-ribosylation factor 6 expression increase in oesophageal adenocarcinoma suggests a potential biomarker role for it.

Venkateswarlu Kanamarlapudi, Salman Tamaddon-Jahromi, Kate Murphy

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Venkateswarlu KanamarlapudiInstitute of Life Science 1, School of Medicine, Swansea University, Singleton Park, Swansea, United Kingdom.ORCID 0000-0002-8739-1483
Salman Tamaddon-JahromiInstitute of Life Science 1, School of Medicine, Swansea University, Singleton Park, Swansea, United Kingdom.
Kate MurphyCellular Pathology, Swansea Bay University Health Board, Singleton Hospital, Swansea, United Kingdom.ORCID 0000-0003-2870-3018
Swansea University · GBSwansea Bay University Health Board · GB

Funding

Biotechnology and Biological Sciences Research Council BB/C515455/2Biotechnology and Biological Sciences Research Council BB/F017596/1Biotechnology and Biological Sciences Research Council BB/S019588/1Medical Research Council G0401232
6 · The paper itself

Abstract

ADP-ribosylation factor 6 small GTPase plays an important role in cell migration, invasion and angiogenesis, which are the hallmarks of cancer. Although alterations in ARF6 expression and activity have been linked to metastatic cancer in one or two tissues, the expression of ARF6 in cancers over a wide range of tissues has not been studied so far. In this report, we analysed the expression of ARF6 mRNA in cancers and corresponding healthy controls from 17 different tissues by real-time qualitative polymerase chain reaction (RT-qPCR). We further evaluated ARF6 protein expression in oesophageal adenocarcinoma (EAC) tissue microarray cores by immunohistochemistry. The ARF6 gene expression levels are highly variable between healthy and cancer tissues. Our findings suggest that the ARF6 gene expression is up-regulated highest in oesophageal cancer. In EAC TMAs, ARF6 protein expression increase correlated with EAC progression. This is the first study to investigate ARF6 gene expression in a wide array of cancer tissues and demonstrate that ARF6 expression, at both mRNA and protein levels, is significantly upregulated in higher grades of EAC, which may be useful in targeting ARF6 for cancer diagnostic and therapeutic purposes.

Indexed as

Up-RegulationAdenocarcinomaADP-Ribosylation Factor 6Biomarkers, TumorCase-Control StudiesDisease ProgressionEsophageal NeoplasmsGene Expression Regulation, NeoplasticHumansNeoplasm GradingTissue Array AnalysisADP-Ribosylation Factor 6ARF6 protein, humanBiomarkers, Tumor

Identifiers

PMID35143561
PMCPMC8830706
OpenAlexW4211167822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.